Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma 1).
Imaging necrosis on MRI scans was assessed and compared to outcome measures of the European Organisation for Research and Treatment of Cancer 26101 phase III trial that compared single-agent lomustine with lomustine plus bevacizumab in patients with progressive glioblastoma.
Methods: MRI in this post hoc analysis was available for 359 patients (lomustine = 127, lomustine + bevacizumab = 232). First, imaging necrosis at baseline being formally measurable (>10 × 10 mm, given 2 slices) was assessed. At weeks 6 and 12 of treatment, it was analyzed whether this necrosis remained stable or increased >25% calculated by 2 perpendicular diameters or whether necrosis developed de novo. Univariate and multivariate associations of baseline necrosis with overall survival (OS) and progression-free survival (PFS) were tested by log-rank test. Hazard ratios (HR) with 95% confidence interval were calculated by Cox model.
Results: Imaging necrosis at baseline was detected in 191 patients (53.2%) and was associated with worse OS and PFS in univariate, but not in multivariate analysis. Baseline necrosis was predictive for OS in the lomustine-only group (HR 1.46, p = 0.018). At weeks 6 and 12 of treatment, increase of baseline necrosis and de novo necrosis were strongly associated with worse OS and PFS in univariate and multivariate analysis (PFS both p < 0.001, OS univariate p < 0.001, multivariate p = 0.0046).
Conclusion: Increase of and new development of imaging necrosis during treatment is a negative prognostic factor for patients with progressive glioblastoma. These data call for consideration of integrating the assessment of imaging necrosis as a separate item into the MRI response assessment criteria 2)
1: Caramanna I, Bottomley A, Drijver AJ, Twisk J, van den Bent M, Idbaih A, Wick W, Pe M, Klein M, Reijneveld JC; EORTC Quality of Life Group and Brain Tumour Group. Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials. Eur J Cancer. 2021 Feb;144:162-168. doi: 10.1016/j.ejca.2020.10.040. Epub 2020 Dec 22. PMID: 33348088.
2: Kessler T, Berberich A, Sadik A, Sahm F, Gorlia T, Meisner C, Hoffmann DC, Wick A, Kickingereder P, Rübmann P, Bendszus M, Opitz C, Weller M, van den Bent M, Stupp R, Winkler F, Brandes A, von Deimling A, Platten M, Wick W. Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Med. 2020 Nov;9(22):8373-8385. doi: 10.1002/cam4.3447. Epub 2020 Sep 29. PMID: 32991787; PMCID: PMC7666733.
3: Johnson RM, Phillips HS, Bais C, Brennan CW, Cloughesy TF, Daemen A, Herrlinger U, Jenkins RB, Lai A, Mancao C, Weller M, Wick W, Bourgon R, Garcia J. Development of a gene expression-based prognostic signature for IDH-wildtype glioblastoma. Neuro Oncol. 2020 Dec 18;22(12):1742-1756. doi: 10.1093/neuonc/noaa157. PMID: 32897363; PMCID: PMC7746941.
4: Kickingereder P, Brugnara G, Hansen MB, Nowosielski M, Pflüger I, Schell M, Isensee F, Foltyn M, Neuberger U, Kessler T, Sahm F, Wick A, Heiland S, Weller M, Platten M, von Deimling A, Maier-Hein KH, Østergaard L, van den Bent MJ, Gorlia T, Wick W, Bendszus M. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Glioblastoma recurrence by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. Radiology. 2020 Oct;297(1):164-175. doi: 10.1148/radiol.2020200978. Epub 2020 Jul 28. PMID: 32720870.
5: D'alessandris QG, Martini M, Cenci T, Di Bonaventura R, Lauretti L, Stumpo V, Olivi A, Larocca LM, Pallini R, Montano N. Tailored therapy for recurrent glioblastoma. Report of a personalized molecular approach. J Neurosurg Sci. 2020 Jun 17. doi: 10.23736/S0390-5616.20.04943-7. Epub ahead of print. PMID: 32550606.
6: Schell M, Pflüger I, Brugnara G, Isensee F, Neuberger U, Foltyn M, Kessler T, Sahm F, Wick A, Nowosielski M, Heiland S, Weller M, Platten M, Maier-Hein KH, Von Deimling A, Van Den Bent MJ, Gorlia T, Wick W, Bendszus M, Kickingereder P. Validation of diffusion MRI phenotypes for predicting response to bevacizumab in Glioblastoma recurrence: post-hoc analysis of the EORTC-26101 trial. Neuro Oncol. 2020 Nov 26;22(11):1667-1676. doi: 10.1093/neuonc/noaa120. PMID: 32393964; PMCID: PMC7690360.
7: Furtner J, Genbrugge E, Gorlia T, Bendszus M, Nowosielski M, Golfinopoulos V, Weller M, van den Bent MJ, Wick W, Preusser M. Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. Neuro Oncol. 2019 Dec 17;21(12):1587-1594. doi: 10.1093/neuonc/noz131. PMID: 31369680; PMCID: PMC6917403.
8: Smits M, Bendszus M, Collette S, Postma LA, Dhermain F, Hagenbeek RE, Clement PM, Liu Y, Wick W, van den Bent MJ, Heiland S. Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting. Eur J Cancer. 2019 Jun;114:89-96. doi: 10.1016/j.ejca.2019.03.007. Epub 2019 May 9. PMID: 31078973.